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Abstract
Aims/hypothesis A subset of obese individuals remains insu-
lin sensitive by mechanisms as yet unclear. The hypothesis
that maintenance of normal subcutaneous (SC) adipogenesis
accounts, at least partially, for this protective phenotype and
whether it can be abrogated by chronic exposure to IL-6 was
investigated.
Methods Adipose tissue biopsies were collected from insulin-
sensitive (IS) and insulin-resistant (IR) individuals undergoing
weight-reduction surgery. Adipocyte size, pre-adipocyte pro-
portion of stromal vascular fraction (SVF)-derived cells,
adipogenic capacity and gene expression profiles of isolated
pre-adipocytes were determined, along with local in vitro IL-6
secretion. Adipogenic capacity was further assessed in re-
sponse to exogenous IL-6 application.
Results Despite being equally obese, IR individuals had sig-
nificantly lower plasma leptin and adiponectin levels and
higher IL-6 levels compared with age-matched IS counter-
parts. Elevated systemic IL-6 in IR individuals was associated
with hyperplasia of adipose tissue-derived SVF cells, despite
higher frequency of hypertrophied adipocytes. SC pre-
adipocytes from these tissues exhibited lower adipogenic ca-
pacity accompanied by downregulation of PPARγ (also
known as PPARG) and CEBPα (also known as CEBPA) and
upregulation of GATA3 expression. Impaired adipogenesis in
IR individuals was further associated with increased adipose
secretion of IL-6. Treatment of IS-derived SC pre-adipocytes
with IL-6 reduced their adipogenic capacity to levels of the IR
group.
Conclusions/interpretation Obesity-associated insulin resis-
tance is marked by impaired SC adipogenesis, mediated, at
least in a subset of individuals, by elevated local levels of IL-6.
Understanding the molecular mechanisms underlying reduced
adipogenic capacity in IR individuals could help target appro-
priate therapeutic strategies aimed at those at greatest risk of
insulin resistance and type 2 diabetes mellitus.
Keywords Adipogenesis . Insulin resistance . Insulin
sensitivity . Interleukin-6 .Obesity .Subcutaneous fat . Type2
diabetesmellitus
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Introduction
Obesity has become a global healthcare priority due to the
comorbidities that accompany excessive adiposity. However,
a number of studies have identified subsets of obese individ-
uals who have fewer cardiovascular risk factors than predicted
by their BMI and who are often referred to as insulin-sensitive
(IS) or metabolically healthy obese [1]. These individuals
maintain insulin sensitivity [1, 2] and exhibit a less pro-
atherogenic lipoprotein profile and less inflammation and hy-
pertension, despite excessive body fat [3, 4]. Currently, key
protective factors accounting for this healthy phenotype are
unclear.
In obesity, exacerbated fat accumulation within adipose
tissues is initially facilitated through local adipocyte hypertro-
phy [5, 6], followed by recruitment of pre-adipocytes, espe-
cially within the larger subcutaneous (SC) depots [7, 8].
Further energy intake leads to visceral fat accumulation, often
accompanied by ectopic deposition in tissues such as liver,
skeletal muscle and heart tissues, causing increased risk of
insulin resistance and type 2 diabetes mellitus [9]. The ability
of the SC depot to efficiently act as a buffer, protecting against
accumulation of fat in visceral tissues, is key to preventing
development of associated pathologies [10].
Pre-adipocytes (CD73+, CD105+, CD166+, CD11b−,
CD14−, CD31−) comprise 15–50% of cells within adipose
tissue and have the ability to differentiate into mature adipo-
cytes (adipogenesis) in response to nutrient excess [11–13]. In
obesity, the number of pre-adipocytes is inversely related to
adipocyte size, predisposing to insulin resistance [6, 14, 15]
independent of sex and body fat level [16]. Accordingly, tis-
sues from insulin resistant individuals (IR) are marked with
fewer, but larger, adipocytes, perhaps reflecting impaired
adipogenesis [17, 18].
Many factors are thought to mediate adipocyte dysfunction
in obesity, including tissue oxidative stress and inflammation
[19, 20]. Lipid-engorged adipocytes secrete greater levels of
cytokines, such as IL-6, IL-β, IL-8 and monocyte
chemoattractant protein-1 [5, 21, 22], which can inhibit adi-
pocyte differentiation [10]. Adipose IL-6 secretion is marked-
ly increased in vivo in obesity, along with systemic elevation,
especially in IR individuals [23–25]. Chronic treatment of
rodent pre-adipocytes, 3T3-F442A and 3T3-L1, with IL-6 in-
creased their autocrine IL-6 secretion and promoted insulin
resistance consistent with downregulation of Glut4 in adipo-
cytes and other pro-adipogenic nuclear factors such as
peroxisome proliferator-activated receptor γ (Pparγ, also
known as PPARG) and CCAAT/enhancer-binding protein α
(Cebpα; also known as CEBPA) [26].
Comparing the adipogenic capacity of SC pre-adipocytes
between IS and IR individuals and examining the impact of
local IL-6 release on this process in primary cultures would
provide valuable insight into the potentially protective mech-
anism associated with the IS group. The aims of the study
were to test two hypotheses: (1) the adipogenic capacity of
SC pre-adipocyte is abrogated in all IR individuals compared
with IS individuals; (2) this lesion is accompanied by greater
release of IL-6 by pre-adipocytes that directly inhibits
adipogenesis.
Methods
Materials IL-6, leptin and adiponectin ELISAs and human
recombinant IL-6 were from R&D systems (Abingdon, UK).
Anti-human antibodies (anti-CD31-FITC, anti-CD166-
PerCP-efluor) were from eBioscience (Hatfield, UK), anti-
CD105-APC, anti-CD45-Alexa fluor 700 and anti-CD11b-
Brilliant Violet 421 were from Biolegend (Cambridge, UK)
and anti-CD73-Brilliant Violet 605 was from BD Bioscience
(Oxford, UK). Insulin ELISAwas fromMercodia Diagnostics
(Uppsala, Sweden). DAPI, LipidTOX Green Neutral Lipid,
Inflammatory Cytokine Human Magnetic 5-Plex and Trizol
were from Life Technologies (Warrington, UK). RT2 Profiler
human adipogenesis PCR arrays and cDNA synthesis kits
were from SABiosciences-Qiagen (Hilden, Germany).
Human Oxidative Stress Magnetic Bead Panel was from
Millipore (Watford, UK). Human white SC-pre-adipocytes
from a lean individual (C-12730) were from PromoCell
(Heidelberg, Germany). Other chemicals and reagents were
from Sigma (Munich, Germany).
Participants Obese and morbidly obese individuals (37
women/20 men) of Arab origin, mainly from Qatar, were re-
cruited from patients undergoing weight reduction surgery at
Hamad Medical Corporation (Doha, Qatar). Inclusion criteria
were severe obesity (BMI ≥35 kg m-2) with co-morbidities
including hypertension, chronic obstructive pulmonary dis-
ease, type 2 diabetes mellitus, sleep apnoea and arthritis, and
morbid obesity (BMI ≥40 kg m-2) with no co-morbidities.
Informed written consent was obtained from all subjects prior
to surgery. Protocols were approved by the Institutional
Review Boards of Hamad Medical Corporation (SCH-
JOINT-111) and Anti-Doping Lab Qatar (SCH-ADL-070)
and were carried out in accordance with the Declaration of
Helsinki as revised in 2008. Blood and SC adipose tissues
biopsies (1–5 g) were collected during surgery and immedi-
ately transported to the laboratory for processing. Systemic
lipids, fasting plasma glucose (FPG) and liver-function
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enzymes were measured using a routine chemistry analyser
(Cobas; Roche Diagnostics, Mannheim, Germany). IL-6, lep-
tin, adiponectin and insulin were determined using commer-
cially available ELISAs. Insulin resistance was calculated by
HOMA-IR [27] with 2.4 as a cut-off point (30th percentile).
Accordingly, individuals were dichotomised into IS (HOMA-
IR <2.4, n=16) and IR (HOMA-IR >2.4, n=41) groups, the
latter including 14 individuals with type 2 diabetes mellitus
(seven treated with metformin, six treated with metformin/
insulin and one treated by dietary modification).
Isolation of stromal vascular fraction cells fromhuman SC
adipose tissue Stromal vascular fraction (SVF) was obtained
by collagenase digestion as previously described [28] and cell
number was quantified per gram of tissue. The SVF pellet was
re-suspended in stromal medium (DMEM-F12 containing
10% [vol./vol.] FBS, 100 units/ml penicillin and 0.1 mg/ml
streptomycin) and maintained at 37°C with 5% CO2 until
confluence, then passaged at 2 × 104 cells/cm2 when
necessary.
Analysis of surface epitopes by FACS Expression of various
cell surface markers was performed as described previously
[29]. Briefly, fixed SVF-derived pre-adipocytes were incubat-
ed with one of the following mouse anti-human antibodies:
CD31-FITC (1:200), NG2-PE (1:200), CD166-PerCP-efluor
(1:40), CD105-APC (1:20), CD45-Alexa fluor 700 (1:100),
CD11b-Brilliant Violet 421(1:40) or CD73-Brilliant Violet
605 (1:20) in 0.5% (wt/vol.) BSA blocking solution. Non-
specific mouse IgG was substituted for the primary antibody
as isotype control. Analysis was performed on FACSCantoII
flow cytometer (BD Bioscience) and analysed with FlowJo
Software v7.6.5 (Three Star, Ashland, OR, USA). Positive
expression was defined as a level of fluorescence greater than
95% of that of the corresponding isotype-matched control
antibody.
Differentiation assays SVF-derived cells (passages 1–3)
were grown in stromal medium overnight then incubated in
differentiation medium (DMEM-F12 containing 3% (vol./
vol.) FBS, 33 μmol/l biotin, 17 μmol/l D-pantothenate,
1 μmol/l dexamethasone, 250 μmol/l methylisobutylxanthine,
0.1 μmol/l human insulin and 5 μmol/l of PPARγ agonist,
rosiglitazone) for 7 days, followed by 12 days in maintenance
medium containing the same components as the differentia-
tion medium, except for methylisobutylxanthine and
rosiglitazone [30].
Determination of adipocyte size Adipose tissue sections
were made from paraffin blocks and stained with
haematoxylin/eosin. Areas of adipocytes were measured in
ten random fields per sample, without prior knowledge of
the experimental groups, using application suite-v4 of a light
microscope (Leica Microsystems, Buffalo Grove, IL, USA).
Viability and differentiation capacity in IS vs IR adipo-
cytes Total number of nuclei (DAPI positive) and differenti-
ated adipocytes (Lipidtox positive), as well as average sizes of
differentiated adipocytes, were scored in 20 fields per well by
ArrayScan XTI (Life Technologies, Grand island, NY, USA)
using the automated spot detection module. Cell viability was
assessed by comparing the number of cells (stained nuclei) at
1 day post seeding with that scored following completion of
differentiation. Differentiation capacity was assessed by cal-
culating the number of Lipidtox-positive cells per total num-
ber of stained nuclei and presented as a percentage
(adipogenic capacity). This was also validated in pre-
adipocytes obtained from a lean individual who showed great-
er than 80% adipogenic capacity (data not shown). For inves-
tigating IL-6-mediated inhibition of differentiation, cells were
grown as above, with or without 20 ng/ml IL-6 for the entire
differentiation/maintenance periods.
Antioxidant profiling of IS v IR differentiated adipocytes
The activity of the reactive oxygen species (ROS) scavenging
enzymes catalase, superoxide dismutase 1 (SOD1), SOD2,
peroxiredoxin 2 (PRX2) and thioredoxin (TRX1) was mea-
sured in equal concentrations of lysates from differentiated
pre-adipocytes of randomly selected IS and IR individuals
using Human Oxidative Stress Magnetic Bead Panel
(H0XSTMAG-18 K) according to manufacturer’s instructions
and assessed by Luminex Flexmap 3D using xPONENT 4.2
software (Austin, TX, USA).
Local cytokine secretion The supernatant media of SC pre-
adipocyte cultures from IS and IR participants were collected
following completion of differentiation. Accumulated levels
of secreted IL-6, IL-1β, TNFα and IL-8 in the last 4 days
before staining were measured using Inflammatory Cytokine
Human Magnetic 5-Plex (Life Technologies) according to
manufacturer’s instructions and assessed by Luminex
Flexmap 3D using xPONENT 4.2 software.
Expression studies RNA was extracted from SC pre-
adipocyte cultures before induction of differentiation, and on
completion, using Trizol following manufacturer’s instruc-
tions. RT2 Profiler human adipogenesis PCR arrays were used
to simultaneously examine the mRNA levels of 89 genes
(including five housekeeping genes) in 384-well plates
according to manufacturer’s protocol. Genes included
PPARγ, CEBPα HSL (encoding hormone-sensitive lipase),
LEP (encoding leptin), SREBF1 (encoding regulatory
element-binding transcription factor 1), GLUT4 and GATA3
(encoding trans-acting T cell-specific transcription factor).
Data were normalised with internal housekeeping genes and
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ΔΔCt was calculated usingΔCt from proliferating IS SC pre-
adipocytes as the control group.
Statistical analysis Comparisons were performed with the
t test, Wilcoxon–Mann–Whitney test, one-way ANOVA or
stepwise linear regression model as appropriate using IBM
SPSS statistics 21 (Armonk, NY, USA). Significance was de-
fined as p≤0.05. Non-parametric tests were used for compar-
ing ordinal or non-normal variables. Power calculations indi-
cated that sample size (N=57) had 100% power to detect a
minimal difference of 30% in mean SC differentiation capac-
ity of IS vs IR and type 2 diabetes mellitus with 34% deviation
from mean value (σ) at a level of α=0.01.
Results
General characteristics of study population Fifty-seven
obese and morbidly obese (BMI 43.3±6.6 kg/m2), relatively
young (35.9±10.2 years), individuals of Arab origin under-
going weight reduction surgery were included. Overall,
participants were hyperinsulinaemic (median [interquartile
range] 79.9 [52.1–124.3] pmol/l), but were then dichotomised
into IS and IR groups based on their HOMA-IR. Accordingly,
28% were insulin sensitive and 72% were insulin resistant,
including 25% with known type 2 diabetes mellitus
(Table 1). Compared with age- and BMI-matched IS partici-
pants, all IR (non-diabetic IR + type 2 diabetes mellitus) indi-
viduals had higher plasma levels of total cholesterol, triacyl-
glycerols, FPG and insulin. They also exhibited higher plasma
levels of liver-function enzymes alanine transaminase (ALT)
and aspartate aminotransferase (AST). Basic patient charac-
teristics are summarised in Table 1.
Insulin resistance-associated adipokine profiling, SVF hy-
perplasia and adipocyte hypertrophy Compared with IS
individuals, all IR (IR + type 2 diabetes mellitus) individ-
uals exhibited a significant reduction in plasma leptin
(Fig. 1a) and adiponectin (Fig. 1b), but had increased IL-6
levels (Fig. 1c). IL-6 levels were positively correlated with
SVF cell number per gram tissue (r= 0.4, p= 0.04, Fig. 1d),
suggesting SVF hyperplasia with increased systemic IL-6
Table 1 General characteristics of study participants
Variable Non-diabetic individuals All IR individuals
IS
(n= 16 [6 M, 10 F])
IR
(n= 27 [(10 M, 17 F])
IS vs IR
p value
T2DM
(n= 14 [(4 M, 10 F])
IR + T2DM
(n= 41, [14 M, 27 F])
IS vs IR + T2D
p value
Age (years) 36.6 (11.8) 33.9 (8.1) 0.3 41.2 (10.8) 36.4 (9.7) 0.96
BMI (kg/m2) 42.9 (5.0) 44.3 (7.1) 0.57 43.5 (7.1) 44.0 (7.0) 0.55
SBP (mmHg) 127.1 (18.3) 126.9 (23.2) 0.69 128.2 (10.2) 127.3 (19.6) 0.98
DBP (mmHg) 71.29 (9.5) 72.78 (14.6) 0.98 73.86 (8.9) 73.2 (12.8) 0.62
MAP (mmHg) 89.90 (9.0) 90.81 (14.6) 0.85 92.4 (9.0) 91.4 (12.9) 0.70
Cholesterol (mmol/l) 4.48 (0.9) 5.0 (0.9) 0.53 5.10 (0.7) 5.0 (0.8) 0.04
LDL-cholesterol (mmol/l) 2.75 (0.6) 3.21 (1.0) 0.94 2.95 (0.8) 3.1 (0.9) 0.16
Triacylglycerol (mmol/l) 1.0 (0.8–1.4) 1.3 (0.9–1.9) 0.50 1.6 (1.3–2.8) 1.4 (1.0–2.1) 0.02
HDL-cholesterol (mmol/l) 1.25 (0.29) 1.20 (0.22) 0.15 1.24 (0.29) 1.2 (0.24) 0.67
FPG (mmol/l) 4.9 (0.5) 5.8 (0.9) 0.11 9.58 (5.81) 7.3 (3.8) <0.01
Insulin (pmol/l) 50.7 (34.0–59.03) 99.3 (79.2–145.2) <0.01 99.3 (71.5–138.2) 99.3 (78.5–141.7) <0.01
HOMA-IR 1.5 (1.1–1.9) 3.9 (3.0–6.6) <0.01 6.0 (3.4–9.0) 4.3 (3.0–7.2) <0.01
Albumin (g/l) 41.5 (36.3–44.0) 42.0 (38.5–45.5) 0.40 42.0 (39.8–44.3) 42.0 (39.0–44.0) 0.34
ALP (U/l) 67.0 (57.0–102.0) 73.0 (58.5–82.3) 0.48 83.5 (60.5–117.3) 74.0 (59.8–85.8) 0.85
ALT (U/l) 17.0 (11.0–21.0) 23.0 (19.0–27.0) 0.03 29.5 (13.8–39.8) 24.0 (17.0–45.0) <0.01
AST (U/l) 18.0 (16.0–19.0) 23.5 (15.0–29.3) 0.02 21.5 (14.0–32.5) 23.0 (15.0–30.8) 0.05
Bilirubin (μmol/l) 8.0 (6.5–13.0) 8.0 (5.8–10.3) 0.54 5.0 (4.0–7.3) 6.5 (5.0–9.0) 0.17
Data are presented as mean (SD) or median (interquartile range)
Obese and morbidly obese male and female patients were recruited and dichotomised into three groups (IS, IR and T2DM)
Components of the metabolic syndrome were measured in IS, IR, T2DM and all IR (IR + T2DM) individuals including BMI, SBP, DBP, MAP, LDL-
cholesterol, HDL-cholesterol, FPG, HOMA-IR, ALP, ALT and AST
Differences between (IS vs IR) and (IS vs all IR) were tested by the independent-sample t test or Mann–Whitney U test
ALP, alkaline phosphatase; DBP, diastolic blood pressure; F, female sex; FPG, fasting plasma glucose; M, male sex; MAP, mean arterial blood pressure;
SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus
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levels. Non-diabetic IR individuals had increased number
of SVF cells by 62% (p= 0.05), compared with IS individ-
uals (data not shown), perhaps reflecting a greater inflam-
matory component or different cellular characteristics of IR
SVF cells.
Assessment of adipocyte size in randomly selected adipose
tissues derived from IS and IR individuals revealed a hetero-
geneity of sizes in both groups with greater frequencies of
small adipocytes (<500 μm2) in IS tissues and large adipo-
cytes (>5000 μm2) in IR tissues (Fig. 1e, f) (p < 0.01).
Whereas the former suggests more plasticity of IS adipocytes,
the latter confirms adipocyte hypertrophy of IR.
Cell surface markers of the pre-adipocyte phenotype in
SVF-derived cells Expression of cell surface markers of the
pre-adipocyte phenotype (CD105+, CD166+, CD73+, CD31−,
CD11b−, CD45−) were investigated in SVF of randomly
selected IS and IR adipose tissue samples. Data indicated a
significantly greater proportion of pre-adipocytes in IS com-
pared with IR samples (88% [78–91%] vs 70% [67–81%];
median [range]; p=0.04) (Fig. 2a, b). This 18% reduction in
pre-adipocyte pool may reflect a reduced plasticity of
IR-derived cells, which may affect their adipogenic capacity.
Insulin resistance-associated impairment of pre-adipocyte
adipogenic capacity The adipogenic capacity of SVF-derived
pre-adipocytes was assessed in all participants. The pre-
adipocytes derived from all IR (non-diabetic IR + type 2 dia-
betes mellitus) individuals exhibited a reduced SC adipogenic
capacity (by 27%, p=0.05) compared with those from IS in-
dividuals (Fig. 3a, b). However, differentiated adipocyte size
(1133±237 vs 1085±93.9 pixels, p=0.6) and average droplet
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Fig. 1 Insulin resistance-
associated adipokine secretion,
SVF cell numbers and adipocyte
size. (a–c) Systemic levels of
leptin (a), adiponectin (b) and
IL-6 (c) were assessed in IS and
IR individuals and in participants
with type 2 diabetes mellitus
(T2DM). (d) Plasma IL-6
concentrations correlated with
SVF cell number per gram of
adipose tissue. (e, f) Adipocyte
sizes within adipose tissues from
IS (white bars) and IR (grey bars)
individuals were compared;
frequencies of small adipocytes
and large adipocytes are shown in
(e) and (f), respectively. Data are
presented as median
± interquartile range (N = 57, as
shown in Table 1) in (a–c) or
frequency histogram (n = 10: IS,
n= 5; IR, n= 5) in (e, f).
Differences between groups were
tested by ANOVA followed by
independent-sample t test to
compare IS vs IR and IS vs all IR;
*p< 0.05 (a–c). Relationship
between circulating IL-6 and SVF
cell number was performed with
Pearson’s correlation (d). A rank-
based two-sample Mann–
Whitney U test was used to
compare frequencies of detected
sizes in IS vs IR (e, f). *p< 0.05
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size (64.5±55.2 vs 55.1±32.8 pixels, p=0.7) were similar in
IS vs all IR individuals (data not shown). Impairment of
adipogenic capacity of IR-derived pre-adipocytes was associ-
ated with downregulation of pro-adipogenic nuclear factors
PPARγ, CEBPα and SREBF1 and upregulation of anti-
adipogenic nuclear factor GATA3 pre-and post-induction of
differentiation (Fig. 3c). Impairment was also marked by
downregulation of mature adipocyte markers HSL, LEP and
GLUT4 (Fig. 3c). This is the first report of impairment in pre-
adipocyte adipogenic potential in insulin resistance, indepen-
dent of obesity, in humans. Differences in adipogenic capacity
between insulin sensitivity and insulin resistance did not re-
flect reduced cell viability in insulin resistance (Fig. 3d) de-
spite increased markers of oxidative stress (Fig. 3e, f).
Role of IL-6 in impairment of pre-adipocyte adipogenesis
To identify mediators of SC differentiation, beyond
hyperinsulinaemia, regression models with variables in
Table 1 were carried out after exclusion of insulin and
HOMA-IR. The models revealed systemic IL-6 to be the main
predictor in all groups (IS + IR + type 2 diabetes mellitus)
(β=−0.3, p=0.03), including the IR (β=−0.4, p=0.05) and
non-diabetic groups (IS + IR) (β=−0.4, p=0.01), explaining
10%, 20% and 20% of SC differentiation, respectively (data
not shown). This suggests a role for IL-6 as a marker or me-
diator of impaired adipogenesis.
To investigate the role of IL-6 in adipogenesis, local IL-6
secretion was determined in cultured pre-adipocytes from IS
and IR individuals. Compared with IS-derived cultures, all IR
(IR + type 2 diabetes mellitus) SC-derived cultures secreted
higher levels of IL-6 (3.4±3.1 vs 6.8±1.8 ng/ml, respective-
ly). Secreted levels of IL-1β, IL-8 and TNFα were also com-
pared between IS- and IR-derived differentiated adipocytes
but neither IL-1β nor IL-8 differed significantly between the
two groups (Fig. 4a). TNFα concentrations were below the
limit of detectability.
Secreted IL-6 and SC adipogenic capacity were inversely
correlated (r=−0.6, p<0.01) (Fig. 4b), suggesting that elevated
secretion of IL-6 may play a role in SC differentiation. SC-
secreted IL-6 also exhibited a negative correlation with
CEBPα expression (r=−0.6, p=0.03) and a positive correla-
tionwithGATA3 expression (r=0.6, p=0.06) (data not shown).
To confirmwhether IL-6 inhibits SC differentiation in IS- and
IR-derived pre-adipocytes, the adipogenic capacity of these cells
was assessed in the presence of exogenous IL-6 (20 ng/ml).
Indeed, treatment of IS-derived cultures with IL-6 reduced SC
adipogenic capacity by 46% (p=0.01) comparedwith the capac-
ity of untreated cells, despite there being no change in cell
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Fig. 2 Cell surface determinants
of pre-adipocyte phenotype in
SVF. Results are based on FACS
quantification of triple-positive
population (CD105+, CD166+,
CD73+) of SVF-derived pre-
adipocytes. (a) Representative
images indicate IR sample stained
with anti-CD105, anti-CD166,
anti-CD73 and corresponding
fluorescence minus one (FMO)
controls. (b) Differences between
IS and IR samples are
summarised in the table. Data are
presented as median and
interquartile range (n= 10: IS,
n= 5; IR, n= 5) and differences
between groups were tested using
the Mann–Whitney U test
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number (p=0.9), to a level similar to that of the IR group.
Differentiation of the IR group was further reduced by 54%
(p<0.01) by IL-6 treatment, with no significant effect on cell
number (p=0.4) (Fig. 4c, d). Thus, the association between im-
paired adipogenesis and both systemic and secreted IL-6 levels
in the IR group suggested a role for IL-6 in abrogating SC
adipogenesis, which was confirmed by IL-6 intervention studies.
Discussion
Emerging data points to loss of adipogenic capacity of SC pre-
adipocytes and alteration in the phenotype of this depot, with
increased hyperplasia of the stromal cells and hypertrophy of
adipocytes being important in the development of insulin re-
sistance and predisposition to type 2 diabetes mellitus [21, 31,
32]. This is the first report that investigates adipogenic capac-
ity, finding a potential role for IL-6 in mediating the process in
IS vs IR tissue from obese non-white individuals. The clinical
data confirmed previously reported heterogeneity of associat-
ed pathology, even among individuals susceptible to insulin
resistance and with morbid obesity. SC pre-adipocytes of the
IS subset preserved their capacity to differentiate, perhaps
facilitating excess energy to be largely stored as triacylglycer-
ols in this depot and lowering ectopic fat deposition, as indi-
cated by the more favourable liver-function variables. Further,
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Fig. 3 Adipogenic capacity, gene expression profile and viability of dif-
ferentiated pre-adipocytes derived from IS and IR individuals.
Differentiation of pre-adipocytes from IS and IR individuals and those
with type 2 diabetes mellitus (T2DM) was quantified by scoring the
percentage of Lipidtox-positive cells to total number of cells (adipogenic
capacity). (a) Representative light-microscopy (LM) images of differen-
tiated adipocytes (scale bar, 200 μm) and Arrayscan (AS; scale bar,
100 μm); the selected fluorescently labelled lipid droplets are shown.
(b) Adipogenic capacity of the pre-adipocytes. (c–f) The expression
profile of genes encoding adipogenic nuclear factors and markers of ma-
ture adipocytes was determined in pre-adipocytes (PA) and differentiated
adipocytes (DA) (c), together with cell viability (white bar, seeding den-
sity; grey bar, density at day 19) (d) and activity of oxidative stress
scavenging enzymes (fluorescence units, FU) in IS (white bar) and IR
(grey bar)-derived cells (e, f). Data are presented as mean ± SEM; N= 57
as in Table 1 in (b) and n= 15 (IS, n= 5; IR, n= 10) in (c–f). Differences
between IS and IR were tested by independent-sample t test; *p< 0.05
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IS-derived pre-adipocytes exhibited a higher pro-adipogenic
and lower anti-adipogenic gene expression profile. These dif-
ferences between insulin sensitivity and insulin resistance,
albeit subtle, may be a consequence of a preponderance of
large adipocytes, prone to forming inflammatory foci, in the
IR group [33], accounting for small but significant differences
in adipogenic capacity in this cohort. Markers of oxidative
stress were also elevated in the IR state. Thus the related
scenario of inflammation and oxidative stress is a likely me-
diator of increased IL-6 secretion in this depot.
The positive correlation between IL-6 levels and SVF cell
numbers suggests a mitogenic effect on all SVF cells
(endothelial, epithelial, macrophages, pre-adipocytes) known
to express its cell surface receptor or able respond to its soluble
form (sIL-6R). IL-6 was selected as a prime candidate based on
previous studies suggesting that chronic exposure of mice to
IL-6 induces insulin resistance in skeletal muscle cells and he-
patocytes [34, 35]. This study provides data that supports pre-
vious findings of elevated IL-6 expression in human fat cells
from IR individuals [23, 36], and the reported positive correla-
tion between secreted IL-6 and adipocyte resistance to insulin
[37]. A negative correlation between secreted IL-6 and SC
adipogenic capacity was apparent, perhaps consequent to IL-6
repression of CEBPα expression, as reported previously in
hepatoma cells [38]. Additionally, GATA-3, shown previously
to bind CEBPα as a critical step in inhibition of pre-adipocyte
differentiation [39], was positively associated with secreted
IL-6, suggesting that the ratio of the two nuclear factors in
response to local secretion of IL-6 might be critical for modu-
lating SC adipogenesis.
While IL-6 levels were inversely related to adipogenic
capacity and treatment with IL-6 in vitro reduced adipogenic
capacity, this reduction was equal in IS and IR cells
(Fig. 4b, d). IR individuals may be expected to be ‘resistant’
to this cytokine because of possible prolonged exposure to it
in vivo; however, this was not apparent in vitro, perhaps due to
IL-6 receptor binding mode and subsequent signal transduc-
tion. IL-6 signals via a heterodimeric receptor complex
consisting of ligand-binding IL-6 α-subunit (IL-6R) and a
signal transducing subunit (gp130). In addition a ligand bind-
ing the soluble form of IL-6R (sIL-6R) is present in both blood
and urine, and is an agonist. While both the membrane-bound
IL-6R and sIL-6R bind the cytokine with equal affinities, the
response to the IL-6/sIL-6R complex in vivo can be substan-
tially different from the response to IL-6 alone [40]. sIL-6R is
generated mainly by proteolytic cleavage of the extracellular
domain of IL-6R by the metalloprotease ADAM 17 [41].
Interestingly, adipocyte differentiation is increased when
ADAM 17 is knocked down [42]. SC adipose tissue from
the human mammary depot demonstrated expression of
IL-6R and gp130 protein in mature adipocytes but not in un-
differentiated adipocyte precursor cells [43]. Blocking IL-6
trans-signalling in rodents prevents high-fat diet-induced adi-
pose tissue macrophage (ATM) recruitment. While in mice
this did not improve insulin resistance, in humans, in the same
study, there were significant correlations between insulin
0
10
20
30
40
50
60
70
Untreated IL-6 Untreated IL-6
IS IR+T2DM
S
ec
re
te
d 
IL
-6
 (
ng
/m
l)
Adipogenic capacity
b
S
ec
re
te
d 
cy
to
ki
ne
s 
(n
g/
m
l) *
a
A
di
po
ge
ni
c 
ca
pa
ci
ty
 (
%
)
c d
*
*
DAPI/Lipidtox
0
2
4
6
8
10
12
0 10 20 30 40 50 60
r=-0.6
IS IS+IL-6
IR IR+IL-6
0
1
2
3
4
5
6
7
IS IR
IL-6
0
0.2
0.4
0.6
0.8
1.0
1.2
IS IR IS IR
IL-8 IL-1β
Fig. 4 Role of IL-6 in the
impairment of pre-adipocyte
adipogenic capacity. (a) Secreted
levels of IL-6, IL-8 and IL-1β
were compared between IS- and
IR-derived differentiated
adipocytes. (b) Correlation
between in vitro secreted IL-6 and
adipocyte differentiation capacity.
(c, d) Effect of treatment with
20 ng/ml IL-6 throughout
differentiation on adipogenic
capacity (representative images;
scale bar, 100 μm (c) were
quantified in IS and IR + type 2
diabetes mellitus (IR + T2DM)
groups (d). Data are presented as
mean ± SEM (n= 21 [IS, n= 7;
IR, n = 14). Differences in paired
groups were tested by paired-
samples t test (a, d) and the
relationship between secreted
IL-6 and adipogenic capacity was
examined with Pearson’s
correlation (b); *p< 0.05
Diabetologia
resistance (as measured by the HOMA-IR), sIL-6R plasma
concentrations and ATM accumulation [44]. We have
assessed the expression of IL-6R and gp130 in differentiated
adipocytes and found them to be comparable in insulin sensi-
tivity and insulin resistance (data not shown). Thus, in vivo
trans-signalling may largely explain the IR cohort’s inability
to undergo adipogenesis. This is currently being investigated
further in cells from IS and IR individuals.
Previous work has focused on studying purified pre-
adipocytes following depletion of inflammatory cells [14, 20].
This study investigated the behaviour of pre-adipocytes within
their natural niche where obesity-induced inflammation plays an
integral role in their pathophysiology [20]. Therefore, depleting
endothelial cells and/or leucocytes would potentially deprive
them of their paracrine effects [45, 46]. Phenotypic characteri-
sation of cellular expression of SVF-derived pre-adipocytes sug-
gested a heterogeneity in the plasticity of SVF cells between
insulin sensitivity and insulin resistance, perhaps accounting
for the reduced adipogenic capacity seen in the IR individuals.
Previous studies have shown impaired adipogenesis in obesity
[14], as well as the presence of two pre-adipocyte subtypes with
respect to their differentiation potential within human pre-
adipocyte populations [47]. It was suggested that the presence
of both subtypes allows plasticity of the progenitor pool over
time in response to various stimuli, such as inflammatory cyto-
kines, with long-term consequences for the cellular composition,
function and adipogenic potential of fat depots [47].
Inherent features of pre-adipocytes were shown previously
to persist in expanded in vitro cultures, including different
size, lipoprotein binding, fatty acid transfer, protein secretion
and response to insulin and lipolytic agents [36]. The observed
ex vivo inherent impairment of SC adipogenic capacity in all
IR individuals may be another feature that persists in vitro,
and can explain the in vivo elevated levels of plasma triacyl-
glycerols and the ectopic deposition in the liver seen in the IR
group of this cohort and reported by others [48].
This study has several limitations. One important differ-
ence between the non-diabetic group (IS + IR) and type 2
diabetes mellitus group is their insulin sensitising and anti-
inflammatory medication (metformin). Despite treatment,
these individuals still show impairment of adipogenesis and
perhaps if untreated, the difference in impairment of
adipogenic capacity would be even greater. It is worth noting
that none of the recruited participants with type 2 diabetes
mellitus were being treated with thiazolidinediones (TZDs),
thus a window for improvement with TZDs through enhance-
ment of pre-adipocyte adipogenesis may still exist. Another
possible limitation is the relatively small size of each of the
three groups, although similar studies had enough power to
detect differences in adipogenic capacity with increased BMI
[14] and with insulin resistance in lean individuals [21].
We show that impaired SC adipogenesis resulting in a re-
duced capacity to store triacylglycerols and accommodate
energy in a physiological manner marks obesity-associated IR
and is mediated, at least in part, through local secretion of IL-6.
These findings suggest that measures aimed at lowering tissue
inflammation are likely to stave off insulin resistance.
Understanding themechanisms underlying greater adipogenesis
in the IS group compared with the IR group, could validate the
therapeutic potential of novel targets, such as CEBPα/GATA3
ratio, as well as heterogeneity in cellular IL-6 signalling.
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